ArticleBMC public health2025
Multi-criteria decision analysis of value evaluation of rare disease medical insurance drugs in China.
Kexin Chen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it